Found this at the YMB | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left)  5-yrs @ $199 (only 31 left)  2-yrs @ $99 (only 29 left)

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10152 of 10162  at  5/1/2020 9:13:09 AM  by

Manny


Found this at the YMB

from Feynman April 30th concerning aat, cf, arwr and vertex. seems that vertex has indeed approached arwr and was rebuffed. could vertex/leerink be puling the strings on this latest take down?

Feynman: "Very interesting read-glad to see new options for CF patients. Clearly ARWR with their RNAi candidate for AAT is further ahead in the clinic (expect an update by mid-year?) and the ARWR CF drug, ARO-ENaC, which should be applicable to all CF patients could be an effective competitor for VRTX drugs (although possibly could be combined, too). Interesting that VRTX , in response to a question, talked about acquiring CF assets: "The first is we look at anything that moves in CF regardless of modality, regardless of stage of development." Given this, I wonder if they approached ARWR re ARO-ENaC but were rebuffed?"


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 240
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...